| Title |
Management of epilepsy in patients with Rett syndrome: perspectives and considerations
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, June 2015
|
| DOI | 10.2147/tcrm.s55896 |
| Pubmed ID | |
| Authors |
Natalija Krajnc |
| Abstract |
Rett syndrome (RTT) is a common neurodevelopmental disorder that appears in infancy with regression of acquired motor skills, loss of purposeful activity, hand stereotypies, loss of acquired spoken language, and seizures. Epilepsy affects the majority of patients in a specific clinical stage of the disease and is drug resistant in approximately one-third of cases. The association of epilepsy and even drug-resistant epilepsy has been reported in certain genotypes of the methyl-CpG-binding protein 2 mutation, which is present in a majority of patients with classical RTT. The evolution of electroencephalographic abnormalities accompanying the clinical development of the syndrome is well described, but much less is known about the seizure semiology and the effectiveness of specific antiepileptic drugs. The aim of this review is to present the clinical and electrophysiological aspects of epilepsy in RTT and the current treatment approach. |
Mendeley readers
The data shown below were compiled from readership statistics for 77 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| Unknown | 76 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 13 | 17% |
| Student > Bachelor | 9 | 12% |
| Unspecified | 8 | 10% |
| Other | 7 | 9% |
| Researcher | 7 | 9% |
| Other | 14 | 18% |
| Unknown | 19 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 22% |
| Agricultural and Biological Sciences | 8 | 10% |
| Unspecified | 8 | 10% |
| Neuroscience | 7 | 9% |
| Nursing and Health Professions | 4 | 5% |
| Other | 10 | 13% |
| Unknown | 23 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 June 2015.
All research outputs
#17,285,668
of 25,374,647 outputs
Outputs from Therapeutics and Clinical Risk Management
#926
of 1,323 outputs
Outputs of similar age
#168,503
of 281,411 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#33
of 43 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,411 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.